Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.84 by 23.91 percent. This is a 48.05 percent increase over earnings of $1.54 per share from the same period last year. The company reported quarterly sales of $480.999 million which beat the analyst consensus estimate of $407.493 million by 18.04 percent. This is a 47.67 percent increase over sales of $325.719 million the same period last year.